Home  /  Resource Library  /  Evaluation and associated risk factors for neutropenia with venetoclax and obinutuzumab in the treatment of chronic lymphocytic leukemia

Evaluation and associated risk factors for neutropenia with venetoclax and obinutuzumab in the treatment of chronic lymphocytic leukemia

Study examined risk of neutropenia associated with obinutuzumab combined with venetoclax for treatment of CLL.